Prevention of Decompensation in Compensated Child‑Pugh A Cirrhosis

Identification of Clinically Significant Portal Hypertension (CSPH)

Liver stiffness measurement (LSM) > 20–25 kPa or platelet count < 150 × 10⁹/L indicates probable or confirmed CSPH, defining patients who need preventive therapy. 1, 2
LSM > 25 kPa predicts CSPH with high certainty; non‑selective beta‑blockers (NSBBs) or carvedilol may be started without prior endoscopy. 1, 2
For LSM 20–25 kPa, endoscopy should be performed if the patient is not already on NSBBs/carvedilol, and treatment initiated when varices are present. 1, 2
LSM < 12 kPa together with platelets > 150 × 10⁹/L effectively excludes CSPH, allowing discharge from CSPH surveillance. 1, 2

All compensated Child‑Pugh A cirrhosis patients with CSPH should receive NSBBs or carvedilol to prevent decompensation events (ascites, variceal bleeding, hepatic encephalopathy). 1, 2
The treatment paradigm has shifted to include all CSPH patients—not only those with high‑risk varices—to avert any decompensating event. 1, 2
The PREDESCI randomized trial demonstrated that beta‑blockers reduce both variceal bleeding and non‑bleeding decompensation, particularly first‑episode ascites. 1, 2
Patients with any size varices and CSPH should be prescribed NSBBs or carvedilol. 1, 2
Beta‑blockers are effective only when a hyperdynamic circulatory state exists (HVPG > 10 mmHg); therefore accurate CSPH identification is essential. 1, 2
Beta‑blockers may be discontinued safely only after regression of CSPH (LSM < 12 kPa and platelets > 150 × 10⁹/L). 1, 2

Hepatitis C: Direct‑acting antiviral cure can lead to CSPH regression; beta‑blockers can be stopped if post‑treatment LSM falls below 12 kPa with adequate platelet count. 1, 2
Hepatitis B: Antiviral suppression improves outcomes in compensated cirrhosis. 3
Metabolic Dysfunction‑Associated Steatotic Liver Disease (MASLD):
- Lifestyle‑induced weight loss of 7–10 % is the cornerstone of management. 4
- GLP‑1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide) or the dual agonist tirzepatide are recommended for patients with type 2 diabetes. 4
- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) are safe for use in Child‑Pugh A cirrhosis. 4
- Resmetirom may be employed where locally approved for advanced fibrosis (F2/F3). 4
- Statins should be continued according to cardiovascular‑risk guidelines; they are safe in compensated cirrhosis and may modestly lower portal pressure. 4
Alcohol‑Related Liver Disease: Complete abstinence is mandatory; even moderate intake rapidly worsens portal hypertension and can trigger decompensation. 5
- Portal pressure rises within 15 minutes after alcohol ingestion (≈0.5 g/kg) in alcoholic cirrhosis. 5

Provide a minimum of 35 kcal /kg body weight per day to maintain energy balance. 4
Ensure 1.2–1.5 g protein /kg body weight per day to preserve muscle mass. 4
Screen all compensated cirrhosis patients for diabetes (prevalence ≈30 %). 6
Metformin is permissible when estimated GFR > 30 mL/min/1.73 m². 4
Sulfonylureas should be avoided because of heightened hypoglycemia risk. 4
GLP‑1 receptor agonists and SGLT2 inhibitors are confirmed safe in Child‑Pugh A cirrhosis. 4
Protein restriction is contraindicated; it worsens sarcopenia and does not prevent hepatic encephalopathy. 4
Metformin must not be used if GFR < 30 mL/min/1.73 m² due to lactic‑acidosis risk. 4

Bacterial infections independently double the risk of decompensation and increase mortality four‑fold in compensated cirrhosis. 5, 3
Clinicians should maintain a high index of suspicion for infection, as bacterial sepsis can precipitate acute‑on‑chronic liver failure. 5, 3

Hepatocellular carcinoma (HCC) screening: Ultrasound with or without AFP every 6 months for all compensated cirrhosis patients, irrespective of etiology. 5
Annual HCC incidence in compensated cirrhosis ranges from 1 % to 7 %. 7
Endoscopic surveillance should follow the LSM‑based algorithm described above. 1, 2
Patients already on NSBBs/carvedilol with LSM > 25 kPa may continue therapy without repeat endoscopy. 1, 2

Do not stop beta‑blockers prematurely; cessation is appropriate only after documented CSPH resolution (LSM < 12 kPa, platelets > 150 × 10⁹/L). 1, 2
Do not impose protein restriction; adequate protein intake supports muscle preservation and does not increase encephalopathy risk. 4
Do not prescribe metformin when renal function is below the safety threshold (GFR < 30 mL/min/1.73 m²). 4